Pharmaceuticals News and Research

RSS

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada.

29 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

GEA Niro selects engineering simulation software from ANSYS

GEA Niro has selected engineering simulation software from ANSYS to optimize equipment design and reduce development time and costs. Based in Denmark, GEA Niro is a world market leader in drying technology for the dairy, food, pharmaceutical and chemical industries and is a core technology center in the GEA Process Engineering business segment in GEA Group.

29 Mar 2010

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

29 Mar 2010

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has granted PROCAPS S.A. exclusive rights to market and sell DAVANAT® to treat cancer in Colombia, South America. Phase ll clinical trial results for late-stage colorectal cancer patients demonstrate that when DAVANAT® is co-administered with the chemotherapy drug 5-FU, survival increased by 46% over the best standard of care and reduced serious adverse events associated with chemotherapy.

29 Mar 2010

Hacker Group formalizes dedicated health insurance marketing practice

Hacker Group, one of the largest direct/digital marketing agencies in the West, today announced that it has formalized a dedicated health insurance marketing practice within the agency. Following years of real world experience within the industry, Hacker Group formed HealthHG to address the highly specialized and complex needs of health insurance marketing.

29 Mar 2010

First Edition: March 29, 2010

Today's headlines showcase reports about the newly enacted health overhaul law and about the political climate facing lawmakers in the post-vote environment.

29 Mar 2010

StockPreacher.com announces investment report featuring ARCA biopharma

StockPreacher.com announces an investment report featuring ARCA biopharma Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

ARYx Therapeutics, Inc. today reported results of operations and provided an update on its products for the fourth quarter and year ended December 31, 2009.

29 Mar 2010

FT and GGT enzymes can be promising targets for treatment of lung cancer

A research team at the Sahlgrenska Academy at the University of Gothenburg, Sweden, has shown in a study that two closely related enzymes could be targets for the treatment of lung cancer. The discovery was made when the researchers blocked the production of the two enzymes in transgenic mice. This resulted in inhibition of cell growth, fewer tumours and greater survival among the mice.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Cegedim Dendrite signs five-year framework agreement with Pierre Fabre Laboratories

Cegedim Dendrite, the world leader in Customer Relationship Management solutions for the Pharmaceutical and Life Sciences industries, entered a five-year framework agreement with Pierre Fabre Laboratories, to strengthen and roll-out medical sales solutions to their international subsidiaries where Cegedim Dendrite solutions have not been implemented.

29 Mar 2010

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

29 Mar 2010

JumpStart Ventures invests $250,000 in Thermalin Diabetes

JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in Thermalin Diabetes Incorporated. The young biopharmaceutical company is developing new insulin treatments for patients with diabetes.

29 Mar 2010

Early stopping of clinical trials result in misleading estimates of treatment effects: Study

An international study of nearly 100 clinical trials that were stopped early due to positive treatment effects has found that many of those effects were exaggerated. The authors of the study — published in the current issue of the Journal of the American Medical Association — recommend that researchers resist pressures to end clinical trials early and continue trials for longer periods before even considering premature termination.

27 Mar 2010

Thermo Fisher Scientific, Eli Lilly expand clinical trial materials supply chain relationship

Thermo Fisher Scientific Inc., the world leader in serving science, and biopharmaceutical company Eli Lilly and Company, announced today that they have expanded their clinical trial materials supply chain relationship. As part of a new five-year agreement, the Fisher Clinical Services business of Thermo Fisher will take over responsibility for Lilly’s in-house clinical trial materials manufacturing, packaging and labeling operations on-site at the Lilly Technology Center – North in Indianapolis. This transition is expected to be completed in the summer of 2010.

From Thermo Fisher Scientific Inc. 27 Mar 2010

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

Ontario announces increase in budget for research and innovation, OBIO applauds

Urgently needed capital should become more accessible to Ontario’s bioscience companies and help create jobs in the biotechnology sector, thanks to Ontario’s 2010 budget. An announced increase in the budget of the Ministry of Research and Innovation coupled with anticipated adjustments to existing funding programs designed to encourage research and innovation are applauded by Ontario Bioscience Industry Organization (OBIO).

27 Mar 2010

Pharmaceuticals News and Research

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

GEA Niro selects engineering simulation software from ANSYS

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

PROCAPS granted exclusive rights to commercialize Pro-Pharmaceuticals' DAVANAT in Colombia

Hacker Group formalizes dedicated health insurance marketing practice

First Edition: March 29, 2010

StockPreacher.com announces investment report featuring ARCA biopharma

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009

FT and GGT enzymes can be promising targets for treatment of lung cancer

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Cegedim Dendrite signs five-year framework agreement with Pierre Fabre Laboratories

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

JumpStart Ventures invests $250,000 in Thermalin Diabetes

Early stopping of clinical trials result in misleading estimates of treatment effects: Study

Thermo Fisher Scientific, Eli Lilly expand clinical trial materials supply chain relationship

Maryland Technology Enterprise Institute director receives President's Award

Ontario announces increase in budget for research and innovation, OBIO applauds

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence